Scientific studies published using CBD

Scientific studies published using CBD

 

The Endocannabinoid System (ECS) is an internal system in our bodies that maintains homeostasis and immunoregulation. The ECS has influence over inflammatory responses, platelet aggregation, blood pressure, heart rate, vasodilatation, and energy balance. The cannabinoid receptors CB1 and CB2 are both members of the superfamily of metabotropic G‐protein‐coupled receptors (GPCRs). CB1 receptors, located mostly in the neurons of the brain however they also are present in the peripheral nervous system. CB2 receptors are found mostly in the immune system[i].

CBD is considered to have pharmacological actions such as anxiolytic, antipsychotic, antiemetic and anti-inflammatory properties[ii]. There have been various therapeutic benefits that scientists have been exploring with CBD as summarised in table 1. These scientific studies presented are not an exhaustive list.

Table 1. Various research topics published in scientific journals using CBD

Research topic that was investigated

Scientific paper

Anxiety

Lemos et al., 2010, Almeida et al., 2013, Shannon et al., 2016 Crippa et al., 2011, Blessing et al., 2015

Cancer

Rocha et al., 2014, Ramer et al., 2014

Cardiovascular diseases

Durst et al., 2007, Booz 2011

Depression

El-alfy et al., 2010, Hsiao et al., 2012, Shoval et al., 2016

Diabetic complications

Weiss et al., 2006, Rajesh et al., 2010

Epilepsy

Maa 2014, Cilio et al., 2014, Millar et al., 2019

Huntington’s disease

Iuvone et al., 2009, Sagredo et al., 2011

Hypoxia ischemia injury

Pazos et al., 2012, Hayakawa et al., 2007

Inflammatory bowel and Chron’s diseases

Sacerdote et al., 2005, De Flilippis et al,. 2011

Inflammatory diseases

Ribeiro et al., 2012, Mecha et al., 2012

Insomnia

Shannon et al., 2016, Shannon et al., 2019

Nausea

Parker et al., 2002

Pain

Crippa et al., 2015, Gomes et al., 2015, Notcutt et al., 2004

Parkinson’s disease

Zuardi et al., 2009, Khoury et al., 2016

Rheumatoid arthritis

Malfait et al., 2000

Schizophrenia

McGuire et al., 2017, Mannucci et al., 2017

These scientific studies presented are not an exhaustive list.

Registered Clinical Trials 

There are over 600 clinical trials registered with the Clinical Trials Register[iii]  key therapeutic areas are summarised in table 2.

The numbers of clinical trials being assessed is likely to grow as more scientific knowledge becomes available around CBD.

 

Table 2.  Summary of clinical trial’s key therapeutic areas

Therapeutic indication: conditions being assessed*

Number of ongoing trials approx.

Parkinson’s disease

172

Pain

58

Epilepsy

29

Cancer

28

Bile duct/ GIT (inflammatory bowel/Chron’s disease)

20

Anxiety and depression

14

Schizophrenia

13

Stroke

6

Autism/Attention Deficit Disorder 

5

Alcohol use disorder

4

Rheumatoid Disease

2

Contraception

2

Multiple Sclerosis

2

*Non exhaustive list

Manipulation of a compromised ECS, by the use of exogenous cannabinoids in vivo can constitute as a potential treatment against various disorders as mentioned above.

i Alfulaij, Naghum et al. “Cannabinoids, the Heart of the Matter.” Journal of the American Heart Association vol. 7,14 e009099. 13 Jul. 2018, doi:10.1161/JAHA.118.009099

ii Alfulaij, Naghum et al. “Cannabinoids, the Heart of the Matter.” Journal of the American Heart Association vol. 7,14 e009099. 13 Jul. 2018, doi:10.1161/JAHA.118.009099 Bergamaschi, Mateus Machado et al. “Safety and side effects of cannabidiol, a Cannabis sativa constituent.” Current drug safety vol. 6,4 (2011): 237-49. doi:10.2174/157488611798280924

iii Clinical Trials.org <https://clinicaltrials.gov/ct2/results?cond=&term=CBD&cntry=&state=&city=&dist=> accessed 3 June 2020

Sign Up to Stay Up to Date!

The first CBD food supplement clinically proven to be safe

Sign up to get 10% off your first order!

By clicking SUBMIT you agree to receiving future communications from Pureis. Read our full privacy policy.

newsletter modal